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Abstract
A wide range of biopeptides potentially able to lower blood pressure through
inhibition of the angiotensin-I converting enzyme (ACE) is produced in fer-
mented foods by proteolytic starter cultures. This work applies a procedure
based on recombinant DNA technologies for the synthesis and expression of
three ACE-inhibitory peptides using a probiotic cell factory. ACE-inhibitory
genes and their pro-active precursors were designed, synthesized by PCR, and
cloned in Escherichia coli; after which, they were cloned into the pAM1 E. coli-
bifidobacteria shuttle vector. After E. coli transformation, constructs carrying
the six recombinant clones were electrotransferred into the Bifidobacterium
pseudocatenulatum M115 probiotic strain. Interestingly, five of the six con-
structs proved to be stable. Their expression was confirmed by reverse tran-
scription PCR. Furthermore, transformed strains displayed ACE-inhibitory
activity linearly correlated to increasing amounts of cell-free cellular lysates. In
particular, 50 lg of lysates from constructs pAM1-Pro-BP3 and pAM1-BP2
showed a 50% higher ACE-inhibitory activity than that of the controls. As a
comparison, addition of 50 ng of Pro-BP1 and Pro-BP3 synthetic peptides to
50 lg of cell-free extracts of B. pseudocatenulatum M115 wild-type strain
showed an average of 67% of ACE inhibition; this allowed estimating the
amount of the peptides produced by the transformants. Engineering of bifido-
bacteria for the production of biopeptides is envisioned as a promising cell
factory model system.
Introduction
In addition to a role in nutrition, proteins may have fur-
ther health benefits due to the release by proteolysis of
encrypted bioactive peptides (BPs). It has been widely
demonstrated that BPs are intervention agents against
chronic human diseases such as hypertension and for
maintaining general well-being (Hartmann & Meisel,
2007; De Leo et al., 2009; Udenigwe & Aluko, 2012). The
use of BPs allows for a number of advantages in compari-
son with chemical drugs, as they come from natural
sources and are therefore safer than synthetic molecules.
Although proteins of animal and plant origins, such as
milk, fish, cereals, eggs, muscles, and peas, have been
exploited as relevant sources for BPs production (Roy
et al., 2010; Gomez-Guillen et al., 2011; Holdt & Kraan,
2011; Ryan et al., 2011; Urista et al., 2011; Lico et al.,
2012), since extraction of BPs from proteins of plant and
animal origin is difficult and costly, companies should be
encouraged to invest in new methods that lead to cheaper
recovery. BPs are considered to be key ingredients in
functional foods, which can be used for struggling against
chronic diseases (Korhonen, 2009). These are classified
according to their physiological activity as antihypertensive
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(Jiang et al., 2010), antimicrobial (Singh & Singh, 2011;
Espitia et al., 2012), antioxidative (Sarmadi & Ismail,
2010; Coda et al., 2012), antitumor (Rizzello et al., 2012),
mineral-binding (Berrocal et al., 1989), and opiate-like
compounds (Varamini et al., 2012), among others. The
most widely studied peptides are those belonging to the
antihypertensive group, which are capable of inhibiting
the angiotensin-I converting enzyme (ACE, EC 3.4.15.1),
a type-I membrane anchored dipeptidyl carboxypeptidase
that is essential for blood pressure regulation and electro-
lyte homeostasis through the renin-angiotensin system
(Hernandez-Ledesma et al., 2011; Phelan & Kerins, 2011).
Three ACE-inhibitory BPs arising from bovine b-casein
have been characterized (Gobbetti et al., 2000; Minervini
et al., 2003). These compounds, named BP1, BP2, and
BP3, correspond, to fragments 57–66, 73–82, and 47–52
of bovine b-casein (A2 allelic variant), respectively. The
pro-active precursors of these BPs (termed as Pro-BP1,
Pro-BP2, and Pro-BP3) were previously expressed as
fusion proteins in Escherichia coli cells, using the GST
expression system. The pro-active precursors were gener-
ated by the addition of two fragments consisting of five
amino acids, at N- and C-term of each BP. After expres-
sion in E. coli as fusion proteins with the GST protein,
BP1, BP2, and BP3 were released from Pro-BPs
using partially purified membrane proteinases iso-
lated from Lactobacillus helveticus PR4 (Losacco et al.,
2007).
In this work, synthetic genes encoding BPs and related
Pro-BPs pro-active precursors were designed, cloned and
expressed using pAM1, an E. coli-Bifidobacterium shuttle
vector. The recombinant plasmids isolated from E. coli
clones were then electrotransferred into the probiotic
strain Bifidobacterium pseudocatenulatum M115. Expres-
sion of the cloned synthetic sequences was assessed by
reverse transcription PCR (RT-PCR) analysis, while cor-
rect activation of the BPs released in cell-free cellular
lysates of the transformed strains was evaluated by the
analysis of their ACE-inhibitory activity.
Materials and methods
Bacterial strains and incubation conditions
Table 1 reports the bacterial strains used in this work.
Bifidobacteria were grown in anaerobiosis at 37 °C in
either MRS (Merck, Darmstad, Germany) or RCM broth
(Merck), both media supplemented with 0.25% (w/v)
Table 1. Bacterial strains, plasmids, and oligonucleotide primers utilized in this work
Item Genotype, phenotype or sequence Source or reference
Strains
Escherichia coli DH10b mcrA, D(mrr-hsdRMS-mcrBC), D(lac-proAB),
D(rec1398), deoR, rpsL, srl-thi-/F’proAB+ lacIqZDM15
Invitrogen
E. coli JM109 endA1, glnV44, thi-1, relA1, gyrA96,
recA1, mcrB+, D(lac-proAB), e14-[F’ traD36,
proAB+, lacIq, lacZDM15], hsdR17, (rK-mK+)
New England Biolabs
Bifidobacterium
pseudocatenulatum M115
Human intestinal isolate, plasmid-free IPLA Laboratory
Collection
Plasmids
pAM1 E. coli-Bifidobacterium shuttle-vector; Apr, Emr; 6100 bp. Alvarez-Martin
et al. (2008)
Oligonucleotides Sequence 5′-3′, restriction sites are underlined, RBS are italicized
BP1 F GATTACGCCAAGCTTAGGAGATGTCTCTGGTGTATCCGTTCCCG This work
BP1 R TGGAGATCCTCTAGATTAAATCGGGCCCGGGAACGGATACAC This work
BP2 F GATTACGCCAAGCTTAGGAGATGAATATTCCGCCGCTGACGCAGACG This work
BP2 R TGGAGATCCTCTAGATTAAATCGGCGTCTGCGTGAGCGG This work
BP3 F GATTACGCCAAGCTTAGGAGATGGATAAGATTCATCCG This work
BP3 R TGGAGATCCTCTAGATTAGAACGGATGAATCTTATC This work
Pro-BP1F GATTACGCCAAGCTTAGGAGATGTTCGCTCAGACGCAGTCTCTGGTGTATCCGTTCCCGGC This work
Pro-BP1-R TGGAGATCCTCTAGATTACGGCAGAGAATTCGGAATCGGGCCGAACGGATACACC This work
Pro-BP2-F GATTACGCCAAGCTTAGGAGATGAATTCTCTGCCGCAGAATATTCCGCCGCTGACGCAG This work
Pro-BP2-R TGGAGATCCTCTAGATTAGAACGGCGGCAGCAGCAGCGGTGTCTGCGTGACCGGCGG This work
Pro-BP3-F GATTACGCCAAGCTTAGGAGATGGAAGATGAACTGCAGGATAAGATTCATCCGTTC This work
Pro-BP3-R TGGAGATCCTCTAGATTAAGACTGCGTCTGAGCGAACGGATGAATCTT This work
Polylinker External F CATGATTACGCCAAGCTT This work
Polylinker External R TTTTGGAGATCCTCTAGA This work
pAM1-R-seq CCACTTGTGTGACCGTGGTGT This work
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L-cysteine (Sigma-Aldrich, St. Louis, MO). Escherichia coli
was grown with shaking at 37 °C in Luria Bertani (LB)
broth (Sambrook & Russell, 2006). Agar plates were pre-
pared by adding 1.5% w/v agar (Oxoid, Basingstoke, UK)
to the same broth media. Antibiotics were added when
required at the following concentrations: ampicillin
100 lg mL1 for E. coli, and erythromycin 5 lg mL1
for bifidobacteria. Isopropyl-b-D-thiogalactoside (IPTG)
and 5-bromo-4-chloro-3-indolyl-b-D-thiogalactopyrano-
side (X-gal) (both from Sigma-Aldrich) were incorpo-
rated to LB plates at respective concentrations of 75 and
60 lg mL1.
Substrates and chemicals
Unless otherwise indicated, hippuryl-L-histidil-L-leucine
(HHL), ACE (from rabbit lung, c. 3 U mg1 of protein),
bovine serum albumin (BSA), tryptone and other
chemicals were all from Sigma-Aldrich. Pro-BP1 (NH2-FA-
QTQSLVYPFPGPIPNSLP-COOH) and Pro-BP3 (NH2-ED-
ELQDKIHPFAQTQS-COOH) synthetic peptides were
purchased from Primm Italia Srl (Milan, Italy) and used
as standard references in RP-HPLC and ACE inhibition
analyses.
Molecular DNA techniques
Cloning, overlapping PCR, colony PCR and DNA manip-
ulation were carried out following standard procedures
(Sambrook & Russell, 2006). Fragments amplified by
overlapping PCR (Delidow, 1997) were cloned into the
T-A cloning vector pGEM-T (Promega, Madison, WI).
DNA amplicons were then purified from agarose gel
using the Montage DNA Gel Extraction Kit (Millipore,
Billerica, MA). The NucleoSpin Plasmid Kit (Macherey-
Nagel, D€uren, Germany) was used for purification of
plasmid DNA from E. coli with reverse transcription PCR
(RT-PCR) performed with the SuperScriptTM First-Strand
Synthesis System (Invitrogen, Carlsbad, CA) using ran-
dom primers.
Plasmid DNA from bifidobacteria was purified follow-
ing the (O’Sullivan & Klaenhammer, 1998) procedure
with minor modifications. In brief, overnight cultures
(5–10 mL) were harvested by centrifugation for 1 min at
maximum speed. The pellet was suspended in 200 lL of a
25% sucrose solution containing lysozyme (30 mg mL1),
mutanolysin (100 units mL1), and RNase A (200 lg
mL1). The mixture was incubated at 37 °C for 30 min.
DNA was precipitated with isopropanol and the pellet
suspended in 320 lL of sterile water. An aliquot of
350 lL of a phenol:chloroform:isopropanol mixture
(24 : 24 : 1) and 200 lL of 7.5 M ammonium acetate
were then added to the solution. After extractions, plas-
mid DNA was precipitated with ethanol, the pellet
washed with ethanol at 70%, dried under vacuum and
suspended in sterile water or TE buffer (10 mM Tris–
HCl, 1 mM EDTA, pH 8.0).
Extraction of total RNA from bifidobacteria was per-
formed using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) with some modifications in the lysis step.
Briefly, cells, grown at an OD600 nm of 0.7–0.8, were har-
vested by centrifugation, the pellet mashed with a pestle
in the presence of liquid nitrogen until a fine powder was
obtained. Samples were then incubated for 1 h at 37 °C
with 200 lL of a TE solution containing lysozyme
(30 mg mL1) and mutanolysin (100 units mL1), later
following the recommendations of the kit protocol.
Amplification and cloning of synthetic genes
encoding BPs and Pro-BPs
Table 1 reports the oligonucleotides used in this work.
Complementary primer pairs were synthesized and used
in overlapping PCR (Delidow, 1997), following amplifica-
tion conditions reported in Table 2. For each construct,
30 PCR cycles were performed. To increase specificity,
progressive longer annealing steps were utilized (Table 2).
Amplifications were performed using High Fidelity Taq
polymerase (Fermentas, Glen Burnie, MD) following con-
ditions recommended by the supplier. Amplified frag-
ments were cloned in pGEM-T. Recombinant clones
were screened by colony PCR and sequenced. Positive
clones were cloned into the E. coli-bifidobacteria shuttle
vector pAM1 (Alvarez-Martin et al., 2008). Subsequent to
Table 2. Amplification scheme to produce the synthetic DNA sequences encoding BPs and Pro-BPs
Step
Gene encoding the peptide
BP1 BP2 BP3 Pro-BP1 Pro-BP2 Pro-BP3
Denaturation 94 °C, 30 s 94 °C, 30 s 94 °C, 30 s 94 °C, 30 s 94 °C, 30 s 94 °C, 30 s
Annealing 35 °C, 30 s 37 °C, 30 s 39 °C, 30 s 37 °C, 30 s 37 °C, 30 s 59 °C, 30 s
40 °C, 5 s 42 °C, 5 s 44 °C, 5 s 42 °C, 5 s 42 °C, 5 s 62 °C, 5 s
45 °C, 5 s 47 °C, 5 s 50 °C, 5 s 50 °C, 5 s 47 °C, 5 s 66 °C, 5 s
50 °C, 10 s 52 °C, 10 s 55 °C, 10 s 60 °C, 10 s 52 °C, 10 s 70 °C, 10 s
Elongation 72 °C, 10 s 72 °C, 10 s 72 °C, 10 s 72 °C, 10 s 72 °C, 10 s 72 °C, 10 s
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E. coli transformation pAM1 clones, carrying bioactive
peptides and their precursor forms, picked up from LB
plates amended with 100 lg mL1 ampicillin, were veri-
fied for their in-frame position by sequencing. Positive
recombinant plasmids carrying in-frame genes were then
electrotransformed into B. pseudocatenulatum M115 as
previously reported (Alvarez-Martin et al., 2008).
Production of water-soluble protein extracts
Cell-free water-soluble protein extracts (CPE) from
recombinant B. pseudocatenulatum and E. coli strains
were obtained by sonication and glass beads treatments.
Briefly, bacterial pellets from overnight cultures were sus-
pended in 4.5 mL of sterile milli-Q water supplemented
with 500 lL of 1 mM phenyl-methyl-sulfonyl fluoride
(PMSF) and 1 g of sterile acid-washed glass beads
(106 lm of diameter; Sigma-Aldrich). Samples were soni-
cated three times (5 min at maximum amplitude, fol-
lowed by 1 min on ice) by a Vibra-Cell VC130 (Sonics &
Materials, Newtown, CT). Protein content was measured
using the Quick StartTM Bradford Protein Assay (BioRad,
Hercules, CA) following the protocol provided by the
manufacturer.
ACE inhibition assay
CPE were used in ACE inhibition assays, following the
method of Nakamura et al. (1995) with minor modifica-
tions. Briefly, increasing volumes of CPE (containing
10–25–50 lg of total protein content) were added to a
5 mM Hip-His-Leu solution and 2 mU of ACE and incu-
bated for 1 h at 37 °C. The hippuric acid liberated was
then extracted with 800 lL of ethyl-acetate, dried in an
oven at 100 °C for 1 h to remove the solvent, and sus-
pended in Milli-Q water (Millipore). Absorbance of the
solutions was then read at 228 nm in an Ultrospec 3100
pro-UV/Visible Spectrophotometer (Amersham-GE
Healthcare, Pittsburgh, PA). Reactions were performed in
triplicate. For all measurements, a control without addi-
tion of ACE inhibitors was included.
RP-HPLC analysis of Pro-BP1 and Pro-BP3 in
bacterial lysates
RP-HPLC was carried out on the CPE obtained from cul-
tures of wild-type and recombinat strains of B. pseudo-
catenulatum M115. In particular, 1 mL of each bacterial
lysate was precipitated by the addition of 4 mL of cold
methanol following the Janini procedure (Janini et al.,
2004). Samples were then centrifuged (17 500 g) for
15 min at 4 °C, and the supernatants were collected and
dried in a SpeedVac concentrator (Thermo-Savant,
Holbrook, NY). Subsequently, all samples were suspended
in 1 mL of Milli-Q water (Millipore), filtered through a
0.22-lm membrane (Millipore) and injected (10 lL) on a
RP-HPLC Zorbax column (SB300 C18;4.6 9 150 mm,
5 lm; Agilent, Waldbronn, Germany) mounted on an
Agilent 1100 apparatus equipped with G1312A binary
pump, G1313 Autosampler, G1316A, G1315B UV-visible
DAD and Agilent Chemstation G2170AA Windows 2000
operating system. The column was equilibrated in water-
acetonitrile (95:5, v/v; solvent A) with 0.1% trifluoro ace-
tic acid (TFA). Peptides were eluted at 1 mL min1 using
a 20-min linear gradient from the solvent A to water-ace-
tonitrile (35:65, v/v; solvent B) containing 0.1% TFA,
with elution monitored by measuring the absorbance at
220 nm. Linear regression analysis (95% confidence
limit), using the least square method, was applied to
relate RP-HPLC peak areas of the Pro-Bp1 and Pro-BP3
peptides to their respective concentration.
CPE extracts were also spiked with Pro-BP1 or Pro-
BP3 synthetic peptides at different concentrations (0.025
and 0.050 mg mL1) and processed as above.
In addition, following RP-HLPC analyses, ACE activity
was tested by adding 50 ng of synthetic Pro-BP1 and
Pro-BP3 to 300 lL (1 mg mL1) of CPE obtained from
B. pseudocatenulatum M115 wild-type strain and incu-
bated for 2 h at 37 °C.
Results
Design of DNA sequences encoding BPs and
Pro-BPs
The three bovine b-casein (A2 allelic variant) derived BPs
(named respectively BP1, BP2, and BP3) and their
pro-active precursors (Pro-BP1, Pro-BP2, and Pro-BP3;
Losacco et al., 2007) were selected to be expressed in a
probiotic strain. Figure 1 shows amino acid sequences
corresponding to BP1, BP2, and BP3 and their precursor
forms, including the corresponding primers. Synthetic
genes expressing BPs and their precursor forms were pro-
duced by overlapping PCR. Primer design took into
account the codon usage of B. pseudocatenulatum.
To ensure optimal expression of BPs and Pro-BPs, a
Shine-Dalgarno ribosome binding site (RBS) consensus
sequence for B. pseudocatenulatum was placed at the 5′
end of all synthetic genes. This sequence was chosen after
the analysis of contigs resulting from the whole genome
shotgun sequencing project of B. pseudocatenulatum DSM
20438 (NCBI: NZ_ABXX00000000.2) using the Biopython
software (Cock et al., 2009). Nucleotide sequences corre-
sponding to positions 100 through +1 of the putative
starting codon of 2032 genes were aligned by PATSEARCH
software (Grillo et al., 2003). Among the four RBS
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sequences already identified in previous reports (AGGAG,
AGGAA, AGAAA, and AGAAG; Nunoura et al., 1997a, b;
MacConaill et al., 2003; Park et al., 2008; Table 3), the
first one showed the highest frequency in the B. pseudo-
catenulatum genome (21%) and was thus selected for
inclusion before the synthetic genes. In addition, HindIII
and XbaI restriction enzyme sites were placed at 5′ and
3′ terminal ends of the coding sequences to facilitate
directional cloning of synthetic genes into the pAM1 vec-
tor (Figs 1 and 2).
Cloning of synthetic genes in E. coli and
bifidobacteria
The cloning procedure, as described in Fig. 2, was per-
formed in two steps. The procedure was necessary to
obtain adequate amount of DNA encoding the synthetic
genes for cloning into bifidobacteria. The first step
involved the cloning of amplified fragments into pGEM-
T Easy Vector with E. coli as host. Recombinant clones
were analyzed by colony PCR and sequencing using Poly-
linker External F and R primer pairs (Table 1). Correct
inserts from the clones were rescued by double digestion
with HindIII and EcoRI and cloned into pAM1 plasmid
vector digested with the same enzymes. The ligation
mixture was transferred into M115 B. pseudocatenulatum.
As a control, the same constructs were also transferred to
E. coli JM109 and DH10b strains. In this way, five of the
six constructs could be recovered in B. pseudocatenulatum
M115, where they proved to be stably maintained. The
exception was pAM1-BP1, as no viable colonies were
obtained by transformation of bifidobacteria with the
pAM1 plasmid vector carrying the BP1-encoding gene.
This suggested that the BP1 peptide might have an anti-
microbial activity against bifidobacteria.
To demonstrate the stability of recombinant plasmids
in B. pseudocatenulatum cells, plasmid DNA isolated
from recombinant strains was used to transform once
again two different E. coli strains (XL1-Blue and
Pro-BP1 gene (101 bp)
Pro-BP1-F 5’ GATTACGCC AAGCTT AGGAG ATG TTC GCT CAG ACG CAG TCT CTG GTG TAT CCG TTC CCG GGC 3’
HindIII  RBS  Met 
Pro-BP1 peptide                          F   A   Q   T   Q   S   L   V   Y   P   F   P   G   P   I
Pro-BP1-R                                                      3’ C CAC ATA GGC AAG GGC CCG GGC TAA GGC TTA AGA GAC GGC ATT AGATCT CCTAGAGGT 5’
P   N   S   L   P
* XbaI
BP1 gene (71 bp)
BP1-F 5’ GATTACGCC AAGCTT AGGAG ATG TCT CTG GTG TAT CCG TTC CCG 3’
HindIII  RBS  Met 
BP1 peptide                          
BP1-R 3’ CAC ATA GGC AAG GGC CCG GGC TAA ATT AGATCT CCTAGAGGT 5’
S   L   V   Y   P   F   P   G   P   I
* XbaI
Pro-BP2 gene (101 pb)
Pro-BP2-F 5’ GATTACGCC AAGCTT AGGAG ATG AAT TCT CTG CCG CAG AAT ATT CCG CCG CTG ACG CAG 3’
HindIII  RBS  Met 
Pro-BP2 peptide                          N   S   L   P   Q   N   I   P   P   L   T   Q   T   P   V
Pro-BP2-R                                                        3’ GGC GGC CAG TGC GTC TGT GGC GAC GAC GAC GGC GGC AAG ATT AGATCT CCTAGAGGT 5’
V   V   P   P   F
* XbaI
BP2 gene (71 pb)
BP2-F 5’GATTACGCC AAGCTT AGGAG ATG AAT ATT CCG CCG CTG ACG CAG ACG 3’
HindIII  RBS  Met 
BP2 peptide                         
BP2-R                                       3’ GGC GAG TGC GTC TGC GGC TAA ATT AGATCT CCTAGAGGT 5’
N   I   P   P   L   T   Q   T   P   V
* XbaI
PRO-BP3 gene (89 pb)
Pro-BP3-F 5’ GATTACGCC AAGCTT AGGAG ATG GAA GAT GAA CTG CAG GAT AAG ATT CAT CCG TTC 3’
HindIII  RBS  Met 
Pro-BP3 peptide     E   D   E   L   Q   D   K   I   H   P   F
Pro-BP3-R                                                    3’ TTC TAA GTA GGC AAG CGA GTC TGC GTC AGA ATT AGATCT CCTAGAGGT 5’
A   Q   T   Q   S
* XbaI
BP3 gene (59 pb)
BP-F 5’ GATTACGCC AAGCTT AGGAG ATG GAT AAG ATT CAT CCG 3’
HindIII  RBS  Met 
BP3 peptide                         
BP-R 3’ CTA TTC TAA GTA GGC AAG ATT AGATCT CCTAGAGGT 5’
D   K   I   H   P   F
* XbaI
Fig. 1. Nucleotide sequences of the corresponding synthetic BP and Pro-BP genes including primers, RBS, enzyme restriction sites, and start and
stop codons. Figure also includes amino acid sequences of Pro-BPs and BPs.
Table 3. PatSearch analysis of putative RBS sequences in
Bifidobacterium pseudocatenulatum genes
Sequence Number of entries Frequency (%)
AGGAG 253 21
AGGAA 202 16
AGAAA 172 14
AGAAG 101 8
Others 502 41
Total 1230 100
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DH10b). Analysis of the recombinant plasmids further
evaluated the integrity of the constructs and the absence
of modifications.
BP expression in bifidobacteria
To confirm the expression of the synthetic genes encod-
ing BP2, BP3, Pro-BP1, Pro-BP2, and Pro-BP3 in bifido-
bacteria, a transcription analysis was carried out. Total
RNA was extracted from recombinant clones and used as
a template in RT-PCRs with random primers. To achieve
specific cDNAs for BP and Pro-BP genes, amplifications
were carried out using the External Polylinker F and R
primer pairs (data not shown). Sequencing of the ampli-
cons obtained demonstrated the effective and reproduc-
ible transcription of the synthetic genes in the
bifidobacteria host strain.
Finally, ACE-inhibitory activity was carried out on pro-
tein extracts isolated from transformed strains carrying
BP or Pro-BP gene-encoding sequences. As a control, a
bifidobacteria strain transformed with pAM1 wild-type
plasmid was used. As can be seen in Table 4, the increase
in ACE-inhibitory activity of CPE belonging to recombi-
nant bifodobacteria expressing the constructs as com-
pared to the controls further confirmed expression of the
synthetic genes.
A further attempt to demonstrate gene expression was
carried out by reverse phase (RP)-HPLC analyses of CPE
extracts of wild and recombinant strains of B. pseudocate-
nulatum M115 carrying Pro-BP1 and Pro-BP3 genes.
Even though the lysates were previously extracted with
methanol, peaks corresponding to the precursor forms of
the bioactive peptides were not observed. By contrast, the
same peptides, synthesized at an HPLC grade and
spiked at two different concentrations (0.025 and
0.050 mg mL1) in the bacterial lysates, were quantita-
tively recovered (about 97%). The failure to retrieve Pro-
BP1 and Pro-BP3 peptides by (RP)-HPLC analysis could
be probably due to their hydrolysis by intracellular endo-
peptidases of the host strain (particularly aminopeptidases
and iminopeptidases), which may be released during the
cell lysis treatment, as previously reported by (Elsoda
et al., 1992). As the precursor peptides were not recov-
ered, isolation of BPs was not attempted.
As reported in Table 4, the presence of BPs and their
precursor forms in the cell-free extracts was finally demon-
strated by the increasing ACE-inhibitory activity of increas-
ing amounts of CPE extracts from the recombinant clones
EcoRI
SacI
KpnI
XbaI
BPs/Pro-BPs
HindIII
pAM1 copG-like
Apr
Emr
6.1 kbp
“Overlapping PCR”
repB
orfX-like
HindIII
SphI
PstI
S
BPs/Pro-BPs
HindIII
70-100bp
Digestion HindIII+XbaI
Ligation
ori pUCXbaI
Emr
EcoRI
SacI
KpnI
alI
XbaI
Apr
orfX-like
copG-likepAM1-BPs/Pro-BPs
6.2 kbp
HindIII
SphI
ori pUC
repBBPs/Pro-BPs
XbaI
SalI
PstI
Fig. 2. General procedure of amplification of Pro-BPs and BPs genes
by overlapping PCR and cloning of the synthetic genes in Escherichia
coli using pGEM-T Easy Vector (Promega) and in Bifidobacterium
pseudocatenulatum M115 using pAM1 cloning vector.
Table 4. ACE inhibitory activity in cell-free lysates isolated from
Bifidobacterium pseudocatenulatum. (A) ACE inhibitory activity in cell-
free cellular lysates obtained from B. pseudocatenulatum transformed
with pAM1 wild-type and pAM1-BPs and pAM1-Pro-BPs recombinant
plasmids*. (B) ACE-inhibitory activity of 50 ng of synthetic Pro-BP1
and Pro-BP3 with or without CPE (1 mg mL1) of bifidobacteria
carrying pAM1-Pro-BP1 and Pro-BP3, respectively*
Recombinant strain
Cellular protein extract amounts (lg)
10 25 50
Activity (%)
(A)
pAM1 wt 0 26  1.5 29  1.5
pAM1-BP2 14  0.7 36  2 54  3
pAM1-BP3 18  1 26  1.5 41  2
pAM1-Pro-BP1 25  1.40 37  2 48  2.5
pAM1-Pro-BP2 5  0.3 14  1 43  2.2
pAM1-Pro-BP3 19  1 32  1.9 58  3
Synthetic peptide
ACE-inhibitory activity (%)
Pro-BPs Synthetic Pro-BPs plus CPE
(B)
Pro-BP1 64  3 70  3.5
Pro-BP3 50  2.5 64  3
*Data are the average of triplicate-independent assays, and the confi-
dence interval was computed at 5%.
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(Table 4). These results confirmed the production and the
expression of bioactive peptides and their precursor forms
even though they were not detectable by RP-HPLC.
To demonstrate the correct intracellular activation in
the biological hypotensive form through the proteolytic
endogenous machinery of B. pseudocatenulatum M115,
synthetic Pro-BP1 and Pro-BP3 were added to water-
soluble protein extracts from B. pseudocatenulatum M115
and incubated for 2 h at 37 °C, after which an ACE inhi-
bition assay was carried out. The results are also summa-
rized in Table 4, and, as compared to the control,
bifidobacteria transformed with the BPs genes showed a
significant increase in their ACE-inhibitory capability.
These results strongly suggest that the increase in ACE
inhibition arose from the activation of the Pro-BPs by
the proteolytic machinery of the host, producing the fully
active ACE-inhibitory BPs.
Discussion
In this study, we established a procedure to obtain ACE-
inhibitory peptides in a probiotic strain by recombinant
DNA techniques. Even though the results are preliminary,
they are relevant because the main advantage of this
approach consists in the engineering of bifidobacteria for
the production of active biopeptides. These could be
used, for example, as supplements in functional foods,
bypassing the purification of complex mixtures of pep-
tides from food matrices or protein hydrolysates. Further-
more, DNA recombinant technologies allow the
modification of single nucleotides to produce from
scratch new highly efficient and selective BPs. B. pseudo-
catenulatum M115 has been proposed over the past dec-
ades as a probiotic candidate along with certain strains
belonging to other species of the human gut (Delgado
et al., 2008). In addition, M115 strain had been already
selected as an optimal cell factory, demonstrating effec-
tiveness for the heterologous expression of interesting
enzymes (Alvarez-Martin et al., 2008).
A number of antihypertensive molecules, including BPs
isolated from natural sources have been already incorpo-
rated into several food and drink products (Hernandez-
Ledesma et al., 2011). Despite their proven usefulness,
purification of BPs from lysates, gastrointestinal digests,
or food stuffs is labor-intensive and costly, prompting us
in this study to explore a new procedure for the produc-
tion of BPs using a recombinant DNA technology.
Indeed, even though several BPs have been successfully
transferred and expressed by recombinant DNA technolo-
gies in bacteria (Renye & Somkuti, 2008), plants (Yang
et al., 2008; Wang et al., 2009; Lico et al., 2012), and
yeasts (Wang et al., 2009), their isolation and industrial
exploitation is rather difficult.
To the best of our knowledge, this is the first work that
reports gene expression of synthetic genes encoding BP2,
BP3, Pro-BP1, Pro-BP2, and Pro-BP3 in bifidobacteria.
Thanks to their ability to colonize the human gut, these
microorganisms could release ACE-inhibitory bioactive
peptides in the intestinal mucosa. Nevertheless, the actual
extent of their assimilation in the bloodstream and their
physiological effects on human health should be evaluated
by appropriate clinical trials. In this regard, further stud-
ies have to be addressed to search for novel food-grade
plasmids that not bear antibiotic resistances. Furthermore,
the over-expression of the synthetic BP-encoding genes
under the control of strong promoters based on constitu-
tive and inducible bifidobacterial genes could enhance BP
production. The capability of bifidobacteria to express
and activate BPs is a fascinating feature for the formula-
tion of innovative functional foods (as for instance,
fermented milks) that could prove useful in the treatment
of mild forms of hypertension.
Using the approach described here, the biopeptides were
expressed and efficiently activated, making it possible to
determine the ACE-inhibitory activity of each individual
BP. For the detection of these small BPs, more sensitive
methods of analysis should be applied. This study is not
exhaustive and other data should be collected to assess the
bioavailability of BPs during digestion. Although our
results leave open many questions, the data reported in
this study are encouraging in the use of B. pseudocatenula-
tum M115 as suitable host strain for the expression of bio-
active molecules. Then, the M115 strain could be
converted in a suitable cell factory model system.
The novelty of this study consists not only in the pro-
cedure used to express the three BPs (BP1, BP2, and
BP3) and their precursor forms, but also in the evidence
of toxicity of the sequence (BP1) whose antimicrobial
activity has never been reported (Losacco et al., 2007).
Further analysis should be aimed at a definitive demon-
stration of cytotoxic activity for BP1.
Acknowledgements
This study was partially supported by the Italian Ministry
of Education, University and Research (MIUR) (Project
FIRB-MERIT 2008 No. RBNE08HWLZ_012 “Basi mo-
lecolari nelle sindromi degenerative correlate con l’invec-
chiamento”) and by the Spanish Ministry of Economy
and Competitiveness to B.M. (ref. AGL2011-24300-ALI).
Luca Losurdo was the recipient of a fellowship from the
Italian Consortium for Biotechnologies. Part of the activi-
ties was also carried out within the Research project
‘Development of innovative food products through bio-
technological, plant design and technological solutions’
(PROINNO_BIT) funded by Italian Ministry of Education,
ª 2012 Federation of European Microbiological Societies FEMS Microbiol Lett 340 (2013) 24–32
Published by Blackwell Publishing Ltd. All rights reserved
30 L. Losurdo et al.
 by guest on June 9, 2016
http://fem
sle.oxfordjournals.org/
D
ow
nloaded from
 
University and Research (MIUR). The authors would like
to thank Dr Federico Baruzzi for his critical reading of
the manuscript.
References
Alvarez-Martin P, Belen Florez A, Margolles A, del Solar G &
Mayo B (2008) Improved cloning vectors for bifidobacteria,
based on the Bifidobacterium catenulatum pBC1 replicon.
Appl Environ Microbiol 74: 4656–4665.
Berrocal R, Chanton S, Juillerat MA, Pavillard B, Scherz JC &
Jost R (1989) Tryptic phosphopeptides from whole casein.
II. Physicochemical properties related to the solubilization
of calcium. J Dairy Res 56: 335–341.
Cock PJA, Antao T, Chang JT et al. (2009) Biopython: freely
available Python tools for computational molecular biology
and bioinformatics. Bioinformatics 25: 1422–1423.
Coda R, Rizzello CG, Pinto D & Gobbetti M (2012) Selected
lactic acid bacteria synthesize antioxidant peptides during
sourdough fermentation of cereal flours. Appl Environ
Microbiol 78: 1087–1096.
De Leo F, Panarese S, Gallerani R & Ceci LR (2009)
Angiotensin converting enzyme (ACE) inhibitory peptides:
production and implementation of functional food. Curr
Pharm Des 15: 3622–3643.
Delgado S, O’Sullivan E, Fitzgerald G & Mayo B (2008) In
vitro evaluation of the probiotic properties of human
intestinal Bifidobacterium species and selection of new
probiotic candidates. J Appl Microbiol 104: 1119–1127.
Delidow BC (1997) Molecular cloning of PCR fragments with
cohesive ends. Mol Biotechnol 8: 53–60.
Elsoda M, Macedo A & Olson NF (1992) The peptide-
hydrolase system of Bifidobacterium species.
Milchwissenschaft 47: 87–90.
Espitia PJP, Soares NDF, Coimbra JSD, de Andrade NJ, Cruz
RS & Medeiros EAA (2012) Bioactive peptides: synthesis,
properties, and applications in the packaging and
preservation of food. Compr Rev Food Sci Food Saf 11:
187–204.
Gobbetti M, Ferranti P, Smacchi E, Goffredi F & Addeo F
(2000) Production of angiotensin-I-converting-enzyme-
inhibitory peptides in fermented milks started by
Lactobacillus delbrueckii subsp bulgaricus SS1 and
Lactococcus lactis subsp cremoris FT4. Appl Environ
Microbiol 66: 3898–3904.
Gomez-Guillen MC, Gimenez B, Lopez-Caballero ME &
Montero MP (2011) Functional and bioactive properties of
collagen and gelatin from alternative sources: a review. Food
Hydrocolloids 25: 1813–1827.
Grillo G, Licciulli F, Liuni S, Sbisa E & Pesole G (2003)
PatSearch: a program for the detection of patterns and
structural motifs in nucleotide sequences. Nucleic Acids Res
31: 3608–3612.
Hartmann R & Meisel H (2007) Food-derived peptides with
biological activity: from research to food applications. Curr
Opin Biotechnol 18: 163–169.
Hernandez-Ledesma B, del Mar Contreras M & Recio I (2011)
Antihypertensive peptides: production, bioavailability and
incorporation into foods. Adv Colloid Interface Sci 165: 23–35.
Holdt SL & Kraan S (2011) Bioactive compounds in seaweed:
functional food applications and legislation. J Appl Phycol
23: 543–597.
Janini GM, Chan KC, Conrads TP, Issaq HJ & Veenstra TD
(2004) Two-dimensional liquid chromatography-capillary
zone electrophoresis-sheathless electrospray ionization-mass
spectrometry: evaluation for peptide analysis and protein
identification. Electrophoresis 25: 1973–1980.
Jiang ZM, Tian B, Brodkorb A & Huo GC (2010) Production,
analysis and in vivo evaluation of novel angiotensin-I-
converting enzyme inhibitory peptides from bovine casein.
Food Chem 123: 779–786.
Korhonen HJ (2009) Bioactive milk proteins and peptides:
from science to functional applications. Aust J Dairy Technol
64: 16–25.
Lico C, Santi L, Twyman RM, Pezzotti M & Avesani L (2012)
The use of plants for the production of therapeutic human
peptides. Plant Cell Rep 31: 439–451.
Losacco M, Gallerani R, Gobbetti M, Minervini F & De Leo F
(2007) Production of active angiotensin-I converting
enzyme inhibitory peptides derived from bovine beta-casein
by recombinant DNA technologies. Biotechnol J 2:
1425–1434.
MacConaill LE, Butler D, O’Connell-Motherway M, Fitzgerald
GF & van Sinderen D (2003) Identification of two-
component regulatory systems in Bifidobacterium infantis by
functional complementation and degenerate PCR
approaches. Appl Environ Microbiol 69: 4219–4226.
Minervini F, Algaron F, Rizzello CG, Fox PF, Monnet V &
Gobbetti M (2003) Angiotensin I-converting-enzyme-
inhibitory and antibacterial peptides from Lactobacillus
helveticus PR4 proteinase-hydrolyzed caseins of milk from
six species. Appl Environ Microbiol 69: 5297–5305.
Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S &
Takano T (1995) Purification and characterization of
angiotensin I-converting enzyme-inhibitors from sour milk.
J Dairy Sci 78: 777–783.
Nunoura N, Ohdan K, Yamamoto K & Kumagai H (1997a)
Expression of the beta-D-glucosidase I gene in
Bifidobacterium breve 203 during acclimation to cellobiose.
J Ferment Bioeng 83: 309–314.
Nunoura N, Fujita T, Ohdan K, Kirihata M, Yamamoto K &
Kumagai H (1997b) Analysis of disaccharides synthesized by
beta-D-glucosidase of Bifidobacterium breve clb and their
assimilation by Bifidobacteria. Biosci Biotechnol Biochem 61:
1033–1035.
O’Sullivan DJ & Klaenhammer TR (1998) Control of
expression of LlaI restriction in Lactococcus lactis. Mol
Microbiol 27: 1009–1020.
Park MS, Kwon B, Shim JJ, Huh CS & Ji GE (2008)
Heterologous expression of cholesterol oxidase in
Bifidobacterium longum under the control of 16S rRNA gene
promoter of bifidobacteria. Biotechnol Lett 30: 165–172.
FEMS Microbiol Lett 340 (2013) 24–32 ª 2012 Federation of European Microbiological Societies
Published by Blackwell Publishing Ltd. All rights reserved
Anti-hyperthensive bioactive peptides in probiotic strains 31
 by guest on June 9, 2016
http://fem
sle.oxfordjournals.org/
D
ow
nloaded from
 
Phelan M & Kerins D (2011) The potential role of milk-
derived peptides in cardiovascular disease. Food Funct 2:
153–167.
Renye JA Jr & Somkuti GA (2008) Cloning of milk-derived
bioactive peptides in Streptococcus thermophilus. Biotechnol
Lett 30: 723–730.
Rizzello CG, Nionelli L, Coda R & Gobbetti M (2012)
Synthesis of the cancer preventive peptide lunasin by lactic
acid bacteria during sourdough fermentation. Nutr Cancer
64: 111–120.
Roy F, Boye JI & Simpson BK (2010) Bioactive proteins and
peptides in pulse crops: pea, chickpea and lentil. Food Res
Int 43: 432–442.
Ryan JT, Ross RP, Bolton D, Fitzgerald GF & Stanton C
(2011) Bioactive peptides from muscle sources: meat and
fish. Nutrients 3: 765–791.
Sambrook J & Russell DW (2006) The Condensed Protocols
from Molecular Cloning: A Laboratory Manual. Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, NY.
Sarmadi BH & Ismail A (2010) Antioxidative peptides from
food proteins: a review. Peptides 31: 1949–1956.
Singh B & Singh R (2011) Antimicrobial effect of peptides
isolated from bovine milk fermented with Lactobacillus
helveticus. Milchwissenschaft 66: 262–265.
Udenigwe CC & Aluko RE (2012) Food protein-derived
bioactive peptides: production, processing, and potential
health benefits. J Food Sci 77: R11–R24.
Urista CM, Fernandez RA, Rodriguez FR, Cuenca AA &
Jurado AT (2011) Review: production and functionality of
active peptides from milk. Food Sci Technol Int 17: 293–
317.
Varamini P, Mansfeld FM, Blanchfield JT, Wyse BD, Smith
MT & Toth I (2012) Synthesis and biological evaluation of
an orally active glycosylated endomorphin-1. J Med Chem
55: 5859–5867.
Wang AP, Wang S, Shen MQ et al. (2009) High level
expression and purification of bioactive human alpha-
defensin 5 mature peptide in Pichia pastoris. Appl Microbiol
Biotechnol 84: 877–884.
Yang LJ, Wakasa Y & Takaiwa F (2008) Biopharming to increase
bioactive peptides in rice seed. J AOAC Int 91: 957–964.
ª 2012 Federation of European Microbiological Societies FEMS Microbiol Lett 340 (2013) 24–32
Published by Blackwell Publishing Ltd. All rights reserved
32 L. Losurdo et al.
 by guest on June 9, 2016
http://fem
sle.oxfordjournals.org/
D
ow
nloaded from
 
